-
1 Comment
Avadel Pharmaceuticals plc is currently in a long term downtrend where the price is trading 4.4% below its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 21.9.
Avadel Pharmaceuticals plc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 311.8% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 131.7% to $-19M since the same quarter in the previous year.
Based on the above factors, Avadel Pharmaceuticals plc gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | IE00BDGMC594 |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Beta | 1.63 |
|---|---|
| Market Cap | 799M |
| PE Ratio | None |
| Target Price | 17.7 |
| Dividend Yield | None |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AVDL using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
